Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:59 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Pharmacovigilance in Gerontopsychiatric Patients
NCT02374567 · Hannover Medical School · PHASE3 · terminated · last registry update 2018-02-28 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Hannover Medical School |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SCN1A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-02-26Phase 3 first posted: The University of Texas Health Science Center, Houston, Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg) + Placebo (NCT03854019)
- 2018-05-01Phase 3 first posted: Tyme, Inc, SM-88 used with MPS (methoxsalen, phenytoin, sirolimus) + Capecitabine, Gemcitabine, and 5-FU (NCT03512756)
- 2018-01-08Phase 3 first posted: Otsuka Pharmaceutical Development & Commercialization, Inc., Placebo + AVP-786 (NCT03393520)
- 2017-11-17Phase 3 first posted: New York State Psychiatric Institute, CI-581a + CI-581b (NCT03344419)
- 2017-10-30Phase 3 first posted: UCB Biopharma SRL, Brivaracetam (BRV) intravenous (iv) + Brivaracetam (BRV) oral (NCT03325439)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision